Effect of Use of DryNites Absorbent Pants on the Rate of Spontaneous Resolution of Paediatric Nocturnal Enuresis (NE)
Launched by KIMBERLY-CLARK CORPORATION · Nov 2, 2020
Trial Information
Current as of June 10, 2025
Completed
Keywords
ClinConnect Summary
Children with severe monosymptomatic NE between 4 and 8 years of age were recruited from study centers in Denmark, Belgium, and the UK. All participants had used absorbents pandt of any manufacturer for at least the previous 6 months. Participants fulfilling the inclusion criteria entered a 4-week run-in period during which they slept wearing the intervention absorbent pant. To be eligible for randomization, participants needed to have 7/7 wet nights in the last week of the run-in period. Eligible participants were then randomly assigned (2:1) to either discontinuation or continuation of ab...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patient aged between 4-8 years at the time of enrollment
- • Have a clinical diagnosis of monosymptomatic primary NE
- • Have been dry in the day for \>/= 6 months prior to enrollment
- • Have on average no more than 1 dry night per month during the past 6 months at enrollment
- • Have an informed consent signed by the their parent(s)/carer(s)
- Exclusion Criteria:
- • Children in foster/court care
- • Have implemented any previous intervention to address NE (use of prescribed alarm schedule, desmopressin, imipramine, anticholinergics) or withdrawal of pants/nappies for \> 7 days in the previous 6 months
- • Have secondary NE
- • Have wetting in the day
- • Have faecal soiling
- • Have known urinary tract disease
- • Have diabetes
- • Receive any regular intake of medication
- • Have a known developmental/neurological disorder
- • Have links to Kimberly-Clark of any kind (including family relations employed by Kimberly-Clark, holding stocks or share in Kimberly-Clark)
About Kimberly Clark Corporation
Kimberly-Clark Corporation is a global leader in personal care and hygiene products, committed to enhancing the health and well-being of individuals and families around the world. With a strong focus on innovation and sustainability, the company develops a wide range of trusted brands, including Huggies, Scott, and Kleenex. As a clinical trial sponsor, Kimberly-Clark actively engages in research to advance product safety and efficacy, ensuring that its offerings meet the highest standards of quality and consumer satisfaction. The company’s dedication to scientific rigor and ethical practices underscores its mission to improve lives through the development of superior health and hygiene solutions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Aalborg, Connor Downs, United Kingdom
Arhus N, Connor Downs, United Kingdom
Ghent, Connor Downs, United Kingdom
Connor Downs, , United Kingdom
Essex, , United Kingdom
Hull, , United Kingdom
Connor, Haley, United Kingdom
Patients applied
Trial Officials
Søren Riting
Principal Investigator
Department of Pediatrics, Aarhus University Hospital, Aarhus, Denmark
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials